Development of leucine rich repeat containing G protein-coupled receptor 5 aptamer based on magnetic assisted rapid aptamer selection platform

Objective: This study aims to screen the aptamers of LGR5 through MARAS platform to regulate the migration, proliferation, and invasion in breast cancer cells. Methods: MARAS platform was used to screen adaptation of LGR5. The expressions of LGR5, β-catenin, c-Myc, Cyclin D1 and DKK1 were detected b...

Full description

Saved in:
Bibliographic Details
Published in:Materials express 2023-02, Vol.13 (2), p.290-296
Main Authors: Zheng, Yajuan, Mo, Qiuping, Tang, Hongchao, Zheng, Qinghui, Guan, Dandan
Format: Article
Language:English
Subjects:
Aptamer
Breast Cancer
Leucine
Lgr5
Maras
Migration
Screening
Tumors
Wound healing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study aims to screen the aptamers of LGR5 through MARAS platform to regulate the migration, proliferation, and invasion in breast cancer cells. Methods: MARAS platform was used to screen adaptation of LGR5. The expressions of LGR5, β-catenin, c-Myc, Cyclin D1 and DKK1 were detected by RT-qPCR and Western blot. Cell viability was analyzed by MTT assay. The capacity of tumor cell migration and invasion were evaluated using wound healing and transwell assays. Results: Anti-LGR5-APtamer was obtained by screening on MARAS platform. Anti-LGR5-aptamer can remarkably inhibit MDA-MB-231 cells growth, such as proliferation, migration and invasion Mechanically, anti-LGR5-aptamer inhibits β-catenin, C-MyC, Cyclin D1 expression and promotes the expression of DKK1. In addition, the Dox-anti-LGR5-aptamer system can enhance the ability of Dox to enter MDA-MB-231 cells, enabling them to exert tumor suppressive function. Conclusions: Screening of LGR5 aptamers through MARAS platform can effectively inhibit the function of LGR5 in breast cancer cells. In addition, using LGR5 aptamers as biological probes loaded with chemotherapy drugs may provide a future strategy for thereapy of breast cancer.
ISSN:2158-5849
2158-5857
DOI:10.1166/mex.2023.2342